This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Do Options Traders Know Something About AdaptHealth Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to AHCO stock based on the movements in the options market lately.
AdaptHealth Corp. (AHCO) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AdaptHealth (AHCO) delivered earnings and revenue surprises of -93.33% and -0.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Insulet (PODD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AdaptHealth Corp. (AHCO) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
AdaptHealth (AHCO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in AdaptHealth Stock?
by Zacks Equity Research
Investors need to pay close attention to AHCO stock based on the movements in the options market lately.
AdaptHealth Corp. (AHCO) Meets Q1 Earnings Estimates
by Zacks Equity Research
AdaptHealth (AHCO) delivered earnings and revenue surprises of 0% and 1.72%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
SYK Stock Falls Despite Q1 Earnings & Sales Beat on Lower '25 EPS View
by Zacks Equity Research
SYK's first-quarter results reflect strong segmental performance, along with a rise in operating margin.
DexCom Stock Rises Despite Q1 Earnings Miss & Lower Margins
by Zacks Equity Research
DXCM's first-quarter 2025 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.
BAX Stock Gains Following Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Baxter reports better-than-expected first-quarter results. However, the company's gross margin contracts. Shares rise in pre-market.
ARAY Stock Down Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Accuray reports solid fiscal third-quarter results, witnessing growth in Product & Services revenues and reduced operating expenses.
GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline
by Zacks Equity Research
Glaukos' first-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.
CAH Q3 Earnings Beat Estimates, '25 EPS View Raised, Stock Gains
by Zacks Equity Research
Cardinal Health's third-quarter fiscal 2025 results benefit from solid Medical and Other segment revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.
CNMD Stock Up On Q1 Earnings & Sales Beat, Raised 2025 Outlook
by Zacks Equity Research
CNMD reports solid first-quarter results, driven by improving sales across both segments.
GE HealthCare Q1 Earnings & Sales Beat Estimates, Net Margin Rises
by Zacks Equity Research
GEHC's first-quarter results reflect strength in the Imaging and Pharmaceutical Diagnostics segments. The bottom line improves on better pricing.
AdaptHealth (AHCO) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
AdaptHealth (AHCO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AHCO or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AHCO vs. SYK: Which Stock Is the Better Value Option?
Abbott (ABT) Q1 Earnings Beat Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 1.87% and 0.56%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Boston Scientific (BSX) Surges 6.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
Boston Scientific (BSX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Strength Seen in ResMed (RMD): Can Its 3.8% Jump Turn into More Strength?
by Zacks Equity Research
ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
PHG Expands Enterprise Imaging in EU: Buy, Sell or Hold the Stock?
by Zacks Equity Research
Philips expands cloud-based imaging in Europe, enhancing AI-driven workflows, collaboration and efficiency in radiology.
AHCO vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
AHCO vs. ABT: Which Stock Is the Better Value Option?
Is AdaptHealth (AHCO) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Aurora Cannabis (ACB) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aurora Cannabis Inc. (ACB) and AdaptHealth Corp. (AHCO) have performed compared to their sector so far this year.
AdaptHealth Corp. (AHCO) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
AdaptHealth (AHCO) delivered earnings and revenue surprises of 34.48% and 3.27%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Down -16.54% in 4 Weeks, Here's Why AdaptHealth (AHCO) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for AdaptHealth (AHCO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.